Wednesday, September 2, 2026 opened flat as investors digested strong results from Dell and Palo Alto Networks while nervously watching a two-year high close on the 10-year Treasury yield and crude oil pushing toward $90 a barrel amid renewed Middle East hostilities. Beneath that cautious headline tape, a genuinely fresh crop of smaller, less-followed names is setting up for Thursday, September 3 — an AI-datacenter partnership announcement, a heavily shorted enterprise-AI name, and a micro-cap diagnostics company riding a low-float rally. Here are 10 stocks to watch tomorrow.
Today’s Market Snapshot
- S&P 500 futures: +0.13% premarket; Nasdaq 100 futures: -0.03%; Dow futures: +0.21%; Russell 2000 futures: +0.36%
- Oil: Crude pushed toward $90 a barrel after an additional tanker was struck by projectiles transiting the Strait of Hormuz Monday night, with renewed Middle East hostilities continuing to stoke inflation concerns.
- Treasury yields: The 10-year yield closed at a two-year high after New York Fed President John Williams told CNBC that higher yields reflect economic strength and that he still sees inflation slowly trending lower.
- Jobs data: ADP reported August private-sector employment of just 38,000, missing the 47,000 consensus — with Friday’s official August nonfarm payrolls report (expected around 45,000 jobs) now looming as the next major catalyst that could either confirm or ease current rate-hike anxiety.
1. Hut 8 Corp. (HUT) — Up Roughly 4% Premarket on an Anthropic-Backed Data Center Deal
| Metric | Value |
|---|---|
| Premarket Move | +4% |
| Sector | Bitcoin mining pivoting to AI infrastructure |
Once known primarily as a Bitcoin miner, HUT 8, jumped in premarket trading Tuesday after Reuters reported the company is developing a major new Texas data center in partnership with Anthropic and Lambda — a significant validation of Hut 8’s pivot toward AI compute infrastructure, placing it in the same conversation as other crypto-miners-turned-AI-hosts that have re-rated sharply this year.
Bull Case vs. Bear Case
Bull case: A confirmed partnership with a leading AI lab like Anthropic gives Hut 8 credible, high-profile validation for its infrastructure pivot — exactly the kind of deal that can support a sustained multiple re-rating rather than a one-day pop.
Bear case: Building large-scale AI data centers is enormously capital-intensive, and Hut 8 will need to prove it can actually finance and execute construction at the scale implied by an Anthropic-level partnership without diluting shareholders heavily along the way.
Technical Levels and Forecast
What to watch tomorrow: Follow-through volume on the Anthropic/Lambda news — a clean hold of today’s premarket gains into Thursday’s close would suggest institutional buyers are backing the AI-pivot thesis, not just day traders.
2. C3.ai, Inc. (AI) — A Squeeze Candidate With Extraordinary Short Interest
| Metric | Value |
|---|---|
| Short Interest | More than 48 million shares |
| Short Interest as % of Float | Over 34% |
| Notional Bearish Bets | More than $523 million |
| Short Interest Trend | Within 2% of its record high |
C3.ai has quietly become one of the most heavily shorted mid-cap AI names on the market, with more than 48 million shares sold short — over 34% of its float and more than $523 million in notional bearish bets, sitting within 2% of the stock’s all-time record short interest. Shares were trading lower Tuesday alongside broader enterprise-software weakness, but the extreme positioning imbalance is exactly the kind of setup traders watch closely for a potential short squeeze if any positive catalyst emerges.
Bull Case vs. Bear Case
Bull case: With such a large percentage of the float sold short, any unexpected positive news — a contract win, a guidance beat, or renewed enterprise-AI enthusiasm — could trigger rapid, forced short-covering that amplifies any upward move well beyond what the fundamental news alone would justify.
Bear case: Short interest this elevated and this persistent typically reflects genuine, sustained bearish conviction about the business itself — C3.ai has faced longstanding questions about its growth durability and path to profitability, and heavy shorting alone is not a reason to expect a reversal without a real catalyst.
Forecast
What to watch tomorrow: Any incremental news flow, however small, given how primed this stock is for an outsized reaction in either direction — squeeze setups like this can move fast once triggered.
3. SOPHiA GENETICS (SOPH) — Riding a Genuine Post-Earnings Volume Spike
| Metric | Value |
|---|---|
| Catalyst | Q2 2026 earnings beat on revenue |
| Sector | Cloud-based genomics/radiomics diagnostics SaaS |
SOPHiA GENETICS, which operates a cloud-based SaaS platform analyzing genomics, radiomics, and clinical data to guide cancer and rare-disease diagnostics, has shown unusually high trading volume tied directly to its Q2 2026 earnings report, which beat revenue expectations and sent shares higher in premarket trading.
Bull Case vs. Bear Case
Bull case: A genuine revenue beat backed by unusual, sustained volume — rather than a single speculative spike — suggests real institutional interest is building in the stock’s precision-medicine data platform thesis.
Bear case: Diagnostics-data SaaS companies at this stage often carry ongoing profitability questions, and a single strong quarter doesn’t guarantee the volume and price momentum will persist without further confirming data points.
Forecast
What to watch tomorrow: Whether SOPH can hold its post-earnings gains through a full trading session — durable volume over multiple days is a stronger signal than a single-day spike.
4. Capital Clean Energy Carriers Corp. (CCEC) — Trading Within 10% of Its 52-Week High
| Metric | Value |
|---|---|
| Contracted Backlog | ~$2.9 billion (up to $4.3 billion including options) |
| Q2 2026 Adjusted EPS Beat | +50% above estimates |
| Distance from 52-Week High | Within 10% |
Capital Clean Energy Carriers, an LNG and clean-energy shipping company, reported a Q2 2026 backlog of approximately $2.9 billion in contracted revenue — potentially rising to $4.3 billion including options — alongside adjusted EPS that beat estimates by a striking 50%. The combination has pushed the stock to within 10% of its 52-week high.
Bull Case vs. Bear Case
Bull case: A multi-billion-dollar contracted backlog provides years of revenue visibility, and continued strong global LNG shipping demand is likely to keep supporting the stock’s momentum toward fresh highs.
Bear case: Shipping and energy-transport stocks remain cyclical and sensitive to global trade and energy-policy shifts — a slowdown in LNG demand or new competitive capacity could pressure day rates and, in turn, the stock’s valuation.
Forecast
What to watch tomorrow: Whether CCEC can push through to a fresh 52-week high — a confirmed breakout on strong volume would validate the backlog-driven bull thesis technically, not just fundamentally.
5. SemiLEDs Corporation (LEDS) — A Low-Float Former Runner Setting Up Again
| Metric | Value |
|---|---|
| Recent Price | ~$3.76 |
| Prior 2026 Range | Ran from $2 to $11 in a prior rally |
| Setup | Bull flag consolidation pattern noted by technical traders |
SemiLEDs has drawn renewed attention from momentum traders as a low-float name that already demonstrated explosive potential earlier this year, running from $2 to $11 before consolidating. The stock is now trading around $3.76, and some technical analysts have flagged a bull-flag chart pattern — a consolidation setup that historically precedes a resumption of the prior uptrend.
Bull Case vs. Bear Case
Bull case: Low-float “former runner” stocks in hot sectors can see rapid, outsized moves when fresh catalysts or momentum-driven buying returns — the stock’s prior $2-to-$11 run demonstrates the mechanical potential is real.
Bear case: Chart patterns like a bull flag are probabilistic, not guaranteed — without a fresh fundamental catalyst, a low-float momentum name can just as easily break down as break out, and this remains a high-risk, speculative trade by nature.
Forecast
What to watch tomorrow: A confirmed break above the recent consolidation range on rising volume would be the technical signal momentum traders are watching for; a breakdown below recent support would likely invalidate the bullish setup.
6. Vishay Intertechnology, Inc. (VSH) — Institutional Buying Meets an AI Power Showcase
| Metric | Value |
|---|---|
| Catalyst | PCIM Asia 2026 exhibition showcase + new institutional stake disclosure |
| Sector | Semiconductors and passive components for AI power infrastructure |
Vishay Intertechnology traded higher Tuesday after announcing it will showcase a comprehensive range of semiconductor and passive component solutions for AI infrastructure and physical AI applications at the PCIM Asia 2026 exhibition. The move was further supported by news of a newly disclosed institutional stake from Connor Clark & Lunn Investment Management, underscoring growing confidence in the company’s positioning within the high-growth AI power-architecture sector.
Bull Case vs. Bear Case
Bull case: Vishay sits in a genuinely underappreciated corner of the AI infrastructure trade — power-delivery components rather than the chips themselves — and fresh institutional buying alongside a major industry showcase suggests the market is starting to notice.
Bear case: Passive-component and power-semiconductor businesses tend to be lower-margin and more commoditized than headline AI chip names, meaning Vishay’s upside from the AI theme may prove more modest than the initial enthusiasm implies.
Forecast
What to watch tomorrow: Any additional detail from the PCIM Asia showcase or further institutional 13F disclosures — both could add to the current positive momentum.
7. bioAffinity Technologies, Inc. (BIAF) — A Micro-Cap Diagnostics Name Riding a Low-Float Surge
| Metric | Value |
|---|---|
| Catalyst | CyPath Lung post-curative surveillance expansion announcement |
| Structural Factor | Recent share consolidation, tight low-float trading dynamics |
bioAffinity Technologies shares surged after the company announced it is positioning its flagship CyPath Lung diagnostic test for post-curative surveillance — monitoring lung cancer recurrence in survivors — expanding the test’s addressable market beyond initial risk assessment. Combined with a recent share consolidation that tightened the stock’s already-thin float, the news has driven sharp, low-volume-amplified price swings.
Bull Case vs. Bear Case
Bull case: Expanding CyPath Lung’s use case into post-treatment cancer surveillance meaningfully broadens the addressable patient population for an already-approved diagnostic, giving physicians a new use case alongside routine imaging.
Bear case: As a micro-cap with a tight, recently-consolidated float, BIAF’s price action can be driven as much by mechanical supply-demand imbalances as by the underlying commercial news — a dynamic that cuts both ways once momentum fades.
Forecast
What to watch tomorrow: Whether trading volume remains elevated — a sustained volume trend alongside price strength would suggest genuine institutional accumulation rather than pure retail momentum.
8. Universe Pharmaceuticals Inc. (UPC) — Up 22% on Pure Speculative Momentum
| Metric | Value |
|---|---|
| Session Move | +22% premarket |
| Identifiable Catalyst | None found — described as speculative momentum in a thinly traded stock |
Universe Pharmaceuticals surged 22% in premarket trading even as the broader market traded lower — the S&P 500 down 0.2%, the Dow down 0.1%, and the Nasdaq down 0.6% in the same session — a sharp divergence from the general market tone. Market analysis attributed the move to speculative momentum in an extremely volatile, thinly traded micro-cap rather than any discrete, identifiable news catalyst.
Bull Case vs. Bear Case
Bull case: Thin-float micro-caps occasionally move ahead of news that hasn’t been publicly disclosed yet — some early momentum traders treat unexplained volume spikes as a signal worth monitoring closely for a follow-up announcement.
Bear case: A move with no identifiable catalyst, in a name this thinly traded, is inherently unpredictable and can reverse just as quickly and steeply as it appeared — this is closer to speculation than an investable thesis without further clarity.
Forecast
What to watch tomorrow: Whether any company disclosure or SEC filing emerges to explain today’s move — absent one, expect elevated volatility to continue without a clear directional bias.
9. Edesa Biotech, Inc. (EDSA) — A Clinical-Stage Name With a Binary Pipeline and Real Cash Burn
| Metric | Value |
|---|---|
| Lead Program | Phase 3 EB05 (paridiprubart) for acute respiratory distress syndrome |
| Secondary Program | Phase 2 EB07 for pulmonary fibrosis |
| Nine-Month Losses | More than $11 million |
Edesa Biotech is a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, with its Phase 3 monoclonal antibody EB05 for acute respiratory distress syndrome as its clearest near-term catalyst, alongside earlier-stage assets EB07 and EB01. Encouraging exploratory signals for paridiprubart in ARDS and acute kidney injury reported in June 2026 have raised hopes that larger trial samples could replicate the effect, but the programs are being funded by recent equity raises that highlight real dilution and funding risk.
Bull Case vs. Bear Case
Bull case: If the encouraging exploratory ARDS and acute kidney injury signals hold up in larger, confirmatory samples, the stock’s current discount and high volatility could be meaningfully reassessed by the market.
Bear case: Ongoing losses of more than $11 million over just nine months, funded through dilutive equity raises, mean shareholders face real value erosion risk even independent of clinical trial outcomes — a genuinely binary, high-risk setup.
Forecast
What to watch tomorrow: Any updates on Phase 3 EB05 trial progress or enrollment — as a binary clinical-stage story, EDSA’s near-term trajectory depends almost entirely on pipeline news flow rather than routine business updates.
10. Rani Therapeutics Holdings, Inc. (RANI) — An Oral Biologics Platform Still Searching for Its Catalyst
| Metric | Value |
|---|---|
| Sector | Oral biologics delivery technology |
| Positioning | Small-cap, frequently cited alongside other clinical-stage names with 2026 catalysts |
The company develops technology aimed at converting injectable biologic drugs into oral formulations — a platform play that, if successful, could meaningfully expand the addressable market for biologic therapies currently limited to injection. The company has been repeatedly cited among small-cap biotech names to watch for 2026 clinical and regulatory milestones, positioning it as a name worth tracking for pipeline updates.
Bull Case vs. Bear Case
Bull case: Oral-delivery technology for biologics addresses a genuine, large unmet need — patient compliance and comfort — and any successful clinical validation could attract significant partnership or licensing interest from larger pharmaceutical companies.
Bear case: Platform technology companies without a near-confirmed catalyst can trade in a prolonged holding pattern, and Rani’s stock is likely to remain range-bound until a specific, dated milestone provides a genuine reason for repricing.
Forecast
What to watch tomorrow: Any forthcoming pipeline or partnership disclosure — absent a specific dated catalyst, expect the stock to continue trading more on broader biotech-sector sentiment than company-specific news.
Sector Sentiment Snapshot
Today’s setups split into three distinct categories: AI-infrastructure-adjacent names riding genuine partnership or institutional-buying news (Hut 8, Vishay, C3.ai’s squeeze setup), post-earnings momentum names with real fundamental support (SOPHiA GENETICS, Capital Clean Energy Carriers), and purely speculative, thin-float micro-caps where price action is running ahead of — or entirely independent from — identifiable news (Universe Pharmaceuticals, SemiLEDs, bioAffinity). That split is a useful lens for tomorrow: names with genuine catalysts (backlog growth, institutional stakes, confirmed partnerships) carry a fundamentally different risk profile than names moving purely on technical or speculative momentum.
Follow TNN for daily stock market news and financial news today.
Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss. Support and resistance levels cited are technical analysis estimates based on historical price data and do not guarantee future price behaviour. Always complete independent due diligence prior to executing equity trades.
About The Author
